Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
J Lopez Bernal, N Andrews, C Gower… - … England Journal of …, 2021 - Mass Medical Soc
Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England …
Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …
Duration of protection against mild and severe disease by Covid-19 vaccines
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant
…, T Rickeard, E Gallagher, C Gower… - … England Journal of …, 2022 - Mass Medical Soc
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England
…, J Stowe, F Kirsebom, S Toffa, R Sachdeva, C Gower… - Nature medicine, 2022 - nature.com
Booster vaccination with messenger RNA (mRNA) vaccines has been offered to adults in
England starting on 14 September 2021. We used a test-negative case–control design to …
England starting on 14 September 2021. We used a test-negative case–control design to …
Effectiveness of COVID-19 vaccines against the Omicron (B. 1.1. 529) variant of concern
…, S Toffa, T Rickeard, E Gallagher, C Gower… - MedRxiv, 2021 - medrxiv.org
Background A rapid increase in cases due to the SARS-CoV-2 Omicron (B.1.1.529) variant
in highly vaccinated populations has raised concerns about the effectiveness of current …
in highly vaccinated populations has raised concerns about the effectiveness of current …
Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and …
Objectives To estimate the real-world effectiveness of the Pfizer/BioNTech BNT162b2 vaccine
and Astrazeneca ChAdOx1 vaccine against Confirmed COVID-19, hospitalisations and …
and Astrazeneca ChAdOx1 vaccine against Confirmed COVID-19, hospitalisations and …
Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK
Background COVID-19 vaccines have been used for 9 months in the UK. Real world data
have demonstrated the vaccines to be highly effective against COVID-19, severe disease and …
have demonstrated the vaccines to be highly effective against COVID-19, severe disease and …
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca)
vaccines by extending the interval between doses up to 12 weeks. In 750 …
vaccines by extending the interval between doses up to 12 weeks. In 750 …
